Title: Therapeutic compositions for intranasal administration which include KETOROLAC

Applicant/Assignee: RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY, A CORPORATION OF SWITZERLAND RECORDATI IRELAND LIMITED

Application No.: 10/792457   Filing Date: 02/Mar/2004

Abstract:

An analgesic/anti-inflammatory pharmaceutical dosage form which comprises an effective amount of an active ingredient selected from the group consisting of racemic 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, optically active forms thereof and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient or diluent, said dosage form being an intranasally administrable dosage form.

Priority: IT1991MI02024 Applic. Date: 1991-07-22; US2001-903665 Applic. Date: 2001-07-13; US1995-383707 Applic. Date: 1995-02-01; US1992-875700 Applic. Date: 1992-04-29

Inventor: SANTUS GIANCARLO [IT]; BOTTONI GIUSEPPE [IT]; BILATO ETTORE [IT]

Title: Tumor-targeted drug delivery systems and uses thereof

Applicant/Assignee: G. GASLINI CHILDREN'S HOSPITAL FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE UNIVERSITY OF ALBERTA

Application No.: 10/853895   Filing Date: 26/May/2004

Abstract:

The present invention relates to targeted delivery systems for delivering therapeutic agents to tumor. The invention further relates to methods of delivering a therapeutic agent to a tumor for the prevention and treatment of cancer by killing tumor cells and tumor-associated endothelial cells. In particular, the present invention provides a tumor-targeted drug delivery system comprising a NGR-containing molecule linked to a delivery vehicle encapsulating a therapeutic agent, preferably a drug, such as a cytotoxic agent or a chemotherapeutic agent. Specifically, the delivery systems of the present invention are capable of delivering an increased amount of therapeutic agent to a tumor as compared to other delivery systems.

In particular, the delivery systems of the present invention are capable of accumulating a higher amount of therapeutic agent in a tumor, or in the vicinity of a tumor cell or tumor-supporting cell, resulting in exposure of the tumor cell and tumor-associated endothelial cell to therapeutic levels of the agent for a longer period of time as compared to other delivery systems. The present invention also describes pharmaceutical compositions comprising the delivery systems of the present invention. The present invention further relates to a tumor treatment comprising an increased amount of therapeutic agent delivered by the system of the present invention as compared to other delivery systems.

The delivery systems and pharmaceutical compositions can be administered to a subject, preferably a human, alone or in combination, sequentially or simultaneously, with other prophylactic or therapeutic agents and/or anti-cancer treatments.

Priority: GB20030012309 Applic. Date: 2003-05-29

Inventor: PONZONI MIRCO [IT]; CORTI ANGELO [IT]; ALLEN THERESA M [CA]

Title: Pharmaceutical compositions and methods of treatment based on diclofenac

Applicant/Assignee: KOWA PHARMACEUTICALS AMERICA, INC

Application No.: 11/132024   Filing Date: 18/May/2005

Abstract:

New pharmaceutical compositions for oral use containing diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other, side effects

in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.

Priority: IT1996MI00992 Applic. Date: 1996-05-17; US2000-524747 Applic. Date: 2000-03-14; US1998-192493 Applic. Date: 1998-11-17; WO1997EP02709 Applic. Date: 1997-05-15

Inventor: REINER ALBERTO [IT]; REINER GIORGIO [IT]

Title: Modified release pharmaceutical composition

Applicant/Assignee: LEK PHARMACEUTICALS D.D

Application No.: 10/740208   Filing Date: 18/Dec/2003

Abstract:

The present invention relates to a novel modified release pharmaceutical composition comprising the coated capsule body, coated or uncoated capsule cap, at least one tablet and granulate comprising active substance.

Priority: SI20020000318 Applic. Date: 2002-12-24; SI20030000246 Applic. Date: 2003-09-24

Inventor: KERC JANEZ [SI]

Title: Ion binding polymers and uses thereof

Applicant/Assignee: RELYPSA, INC

Application No.: 10/965274   Filing Date: 13/Oct/2004

Abstract:

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

Priority: US2004-814527 Applic. Date: 2004-03-30; US2004-814749 Applic. Date: 2004-03-30; US2004-813872 Applic. Date: 2004-03-30

Inventor: CHARMOT DOMINIQUE [US]; CHANG HAN TING [US]; KLAERNER GERRIT [US]; COPE MICHAEL JAMES [US]; LIU MINGJUN [US]; LIU FUTIAN [US]; BUYSSE JERRY [US]; CONNOR ERIC [US]; MONG TONY KWOK-KONG [TW]; SHAO JUN [US]; MADSEN DEIDRE [US]

Title: Delivery of physiological agents with in-situ gels comprising anionic polysaccharides

Applicant/Assignee: CARRINGTON LABORATORIES, INC

Application No.: 10/652622   Filing Date: 29/Aug/2003

Abstract:

In-situ gelation of a pectic substance. Composition, method of preparation, and method of use of a pectin in-situ gelling formulation for the delivery and sustained release of a physiologically active agent to the body of an animal. The pectin can be isolated from Aloe vera.

Priority: US2001-795897 Applic. Date: 2001-02-28

Inventor: NI YAWEI [US]; YATES KENNETH M [US]

Title: Dosage form and method for producing the same

Applicant/Assignee: ROEHM GMBH & CO. KG

Application No.: 10/512860   Filing Date: 15/Nov/2004

Abstract:

The invention relates to a process for producing a coated drug form or a drug form in the form of an active ingredient matrix, by processing a copolymer, an active pharmaceutical ingredient, a core if present and/or pharmaceutically customary excipients in a conventional manner by melting, injection molding, extrusion, wet granulation, casting, dipping, spreading, spraying or compression to form a coated drug form and/or to form an active ingredient matrix, characterized in that a copolymer is used which is composed of 20 to 33% by weight methacrylic acid, 5 to 30% by weight methyl acrylate, 20 to 40% by weight ethyl acrylate and more than 10 to 30% by weight butyl methacrylate and, if desired, 0 to 10% by weight further vinylically copolymerizable monomers, with the proviso that the glass transition temperature of the copolymer in accordance with ISO 11357-2, section 3.3.3,

is 55 to 70 DEG C. The invention further relates to the drug form produced in accordance with the invention, to the copolymer, and to the use thereof.

Priority: DE20031019458 Applic. Date: 2003-04-29; WO2004EP02061 Applic. Date: 2004-03-02

Inventor: PETEREIT HANS-ULRICH [DE]; MEIER CHRISTIAN [DE]; SCHULTES KLAUS [DE]

Title: Microparticles with adsorbed polypeptide-containing molecules

Applicant/Assignee: NOVARTIS VACCINES AND DIAGNOSTICS, INC

Application No.: 10/505250   Filing Date: 13/May/2005

Abstract:

Microparticles with absorbed polypeptide-containing molecules formed without the use of surfactant, methods of making such microparticle compositions, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(alpha-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like. Preferred polymers are poly(D,L-lactide-co-glycolides), more preferable those having a lactide/glycolide molar ratio ranging from 40:60 to 60:40 and having a molecular weight ranging from 20,000 Daltons to 70,000 Daltons. Preferred polypeptide containing molecules are bacterial and viral antigens (including HIV antigens, meningitis B antigens, streptococcus B antigens, and Influenza A hemagglutinin antigens).

Priority: US20020358315P Applic. Date: 2002-02-20; WO2003US05017 Applic. Date: 2003-02-20

Inventor: O'HAGAN DEREK [US]; SINGH MANMOHAN [US]; KAZZAZ JINA [US]

Title: Natural immunostimulant compositions, methods for obtaining the same and pharmaceutical formulations thereof

Applicant/Assignee: MMI CORPORATION

Application No.: 10/831101   Filing Date: 26/Apr/2004

Abstract:

A natural immunostimulant composition for the treatment of immunodeficiency, the composition comprising extract of plant Symplocos racemosa and/or plant Prosopis glandulosa and a pharmaceutically acceptable carrier is disclosed. Also disclosed are methods for obtaining the plant extract, methods for preparing the composition and methods of treating diseases related to immunodeficiency.

Priority:

Inventor: MITRA SHANKER KUMAR [IN]; SAXENA EKTA [IN]; DIXIT MALLIKARJUN NARAYAN [IN]

Title: Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/038658   Filing Date: 18/Jan/2005

Abstract:

The present invention relates to novel pharmaceutical compositions based on fluorene carboxylic acid ester derived anticholinergics of formula 1 and soluble TNF receptor fusion proteins, processes for preparing them and their use in the treatment of respiratory diseases.

Priority: EP20040003896 Applic. Date: 2004-02-20; US20040559855P Applic. Date: 2004-04-06

Inventor: MEADE CHRISTOPHER JOHN MONTAGUE [DE]; PAIRET MICHEL [DE]; PIEPER MICHAEL P [DE]

Title: Combination of polyvinyl acetate with water-insoluble, acid-insoluble, or alkali-insoluble polymers used for the production of film coatings with highly controlled release and high stability

Applicant/Assignee: BASF AKTIENGESELLSCHAFT

Application No.: 10/507607   Filing Date: 14/Sep/2004

Abstract:

The invention relates to the combination of polyvinyl acetate and water-insoluble, acid-insoluble, or alkali-insoluble polymers used for producing film coatings for forms of administration in which agents are released in a controlled manner, and methods for the production thereof. The controlled-release properties can be specifically adjusted by means of said combinations, resulting in films having excellent mechanical stability and storage stability. In particular, agents are released independent of the pH by means of the inventive forms of administration.

Priority: DE20021011289 Applic. Date: 2002-03-14; WO2003EP02455 Applic. Date: 2003-03-11

Inventor: KOLTER KARL [DE]; BODMEIER ROLAND [DE]; DASHEVSKIY ANDRIY [DE]

Title: Polymorphs of cabergoline

Applicant/Assignee: IVAX PHARMACEUTICALS S.R.O

Application No.: 10/841813   Filing Date: 07/May/2004

Abstract:

Provided are new crystalline Forms VIII, IX, XI, XII, XIV, XV, XVI, XVII, and XVIII of cabergoline. Also provided are novel processes for preparation of cabergoline Form I, Form II, Form VII, and amorphous cabergoline.

Priority: US20030468887P Applic. Date: 2003-05-08; US20040539494P Applic. Date: 2004-01-27

Inventor: BEDNA HACEK OVER R ROMAN [CZ]; CVAK LADISLAV [CZ]; JEGOROV ALEXANDR [CZ]; SOBOTIK ROMAN [CZ]

Title: Pharmaceutical composition

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 11/523771   Filing Date: 20/Sep/2006

Abstract:

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Priority: JP19950153500 Applic. Date: 1995-06-20; US2004-937494 Applic. Date: 2004-09-10; US2003-462793 Applic. Date: 2003-06-17; US2002-095453 Applic. Date: 2002-03-13; US2001-973689 Applic. Date: 2001-10-11; US1999-453521 Applic. Date: 1999-12-03; US1999-280710 Applic. Date: 1999-03-30; US1998-057465 Applic. Date: 1998-04-09; US1996-667979 Applic. Date: 1996-06-19

Inventor: IKEDA HITOSHI [JP]; SOHDA TAKASHI [JP]; ODAKA HIROYUKI [JP]

Title: Process for preparation of a sterile suspension of corticosteroid particles for the administration by inhalation

Applicant/Assignee: CHIESI FARMACEUTICI S.P.A

Application No.: 10/510232   Filing Date: 11/Apr/2005

Abstract:

A process for the preparation of aqueous suspensions of sterile micronized drug particles, in particular corticosteroid, to be administered by inhalation, which produces homogenous dispersions of particles characterized by optimal size and size distribution is disclosed. The process is carried out by using a turboemulsifier equipped with a high-power turbine and connected to a loading hopper.

Priority: WO2003EP03916 Applic. Date: 2003-04-15; IT2002MI00808 Applic. Date: 2002-04-17

Inventor: SAMBUCO BARBARA [IT]; PIROTTA DANIELE [IT]

Title: Stable amorphous forms of montelukast sodium

Applicant/Assignee: CHEMAGIS LTD

Application No.: 11/048746   Filing Date: 03/Feb/2005

Abstract:

An amorphous form of montelukast sodium and a montelukast sodium lactose co-precipitate, processes for producing same, pharmaceutical compositions containing same and methods of treatment utilizing same are disclosed.

Priority: US20040541052P Applic. Date: 2004-02-03

Inventor: ALNABARI MOHAMMED [IL]; SERY YANA [IL]; ADIN ITAI [IL]; ARAD ODED [IL]; KASPI JOSEPH [IL]

Title: Systems and methods for non-destructive mass sensing

Applicant/Assignee: NOVARTIS PHARMA AG

Application No.: 11/999316   Filing Date: 04/Dec/2007

Abstract:

The invention provides systems and methods for measuring the mass of a substance. In one method, energy is applied to a substance and a response resulting from the application of energy as measured. The mass of the substance is then determined based at least in part on the measured response.

Priority: US2000-731317 Applic. Date: 2000-12-06; US19990172316P Applic. Date: 1999-12-17

Inventor: NANTEL NORMAND [US]; SMITH ADRIAN [US]; CHEU SCOT [US]; PARKS DERRICK J [US]; GHANDHI JAMSHED [US]

Title: Ion binding polymers and uses thereof

Applicant/Assignee: RELYPSA, INC

Application No.: 11/096209   Filing Date: 30/Mar/2005

Abstract:

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

Priority: US2004-965274 Applic. Date: 2004-10-13; US2004-814527 Applic. Date: 2004-03-30; US2004-814749 Applic. Date: 2004-03-30; US2004-813872 Applic. Date: 2004-03-30

Inventor: CHARMOT DOMINIQUE [US]; CHANG HAN TING [US]; KLAERNER GERRIT [US]; COPE MICHAEL J [US]; LIU MINGJUN [US]; LIU FUTIAN [US]; BUYSSE JERRY M [US]

Title: Enteric coated oral pharmaceutical to erode kidney stones

Applicant/Assignee: MED FIVE, INC

Application No.: 11/066621   Filing Date: 25/Feb/2005

Abstract:

A treatment protocol by which a renal stone patient is administered a chelating agent, generally once a day and preferably by mouth, during a treatment phase and is later administered the same chelating agent once a week, during a "maintenance" phase. The chelating agent is most preferably ethylene diamine tetraacetic acid (EDTA) and may be provided in a dosage form having an enteric coating and at least one external cathode and at least one external anode to create a galvanic current upon contact of the dosage form with the patient's intestinal contents.

Priority: US20040547909P Applic. Date: 2004-02-26

Inventor: KEITH ALEC D [US]; CRISP WILLIAM E [US]

Title: Sustained-release microgranules containing gingko biloba extract and the process for manufacturing these

Applicant/Assignee: ETHYPHARM

Application No.: 10/574923   Filing Date: 19/May/2006

Abstract:

The subject of the present invention is a new stable herbal drug formulation in the form of sustained-release microgranules containing Gingko Biloba extract as well as the process for preparing it.

Priority: EP20030292512 Applic. Date: 2003-10-10; WO2004IB03542 Applic. Date: 2004-10-11

Inventor: MARECHAL DOMINIQUE [CA]; YANG WEI-HONG [CN]; HU YU-ZHANG [CN]

Title: Impregnated powder improving bioavailability and/or solubility and method of production

Applicant/Assignee: SAS GALENIX INNOVATIONS

Application No.: 10/547797   Filing Date: 05/Mar/2004

Abstract:

This invention relates to an impregnated powder for increasing the bioavailabilty and/or the solubility of at least one active principle comprising a solid, inert support in a particle form impregnated by a liquid medium comprising a hydrophobic phase and optionally a hydrophilic phase, at least one surfactant and at least one active principle dissolved in at least one of said phases, wherein said active principle(s) is(are) also present in at least one of said phases in the form of a suspension. Such an impregnated powder is used as a base for various preparations in the pharmaceutical, parapharmaceutical and cosmetic field, in the food complement field and in the food processing industry.

Priority: FR20030002802 Applic. Date: 2003-03-06; WO2004FR00541 Applic. Date: 2004-03-05

Inventor: BESSE JEROME [FR]; BESSE LAURENCE [FR]; ALPHONSE MYRIAM [FR]

Title: SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF

Applicant/Assignee: ESSENTIALIS, INC

Application No.: 12/391990   Filing Date: 24/Feb/2009

Abstract:

Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

Priority: US2006-614044 Applic. Date: 2006-12-20; US20060756941P Applic. Date: 2006-01-05; US20060854740P Applic. Date: 2006-10-27

Inventor: COWEN NEIL M [US]; YAMOUT KHALED A [US]

Title: MODIFIED RELEASE FORMULATIONS OF A BUPROPION SALT

Applicant/Assignee: BIOAVAIL LABORATORIES BIOVAIL LABORATORIES INTERNATIONAL S.R.L

Application No.: 11/774109   Filing Date: 06/Jul/2007

Abstract:

The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

Priority: US2007-751768 Applic. Date: 2007-05-22; US2006-475252 Applic. Date: 2006-06-27; US20050693906P Applic. Date: 2005-06-27

Inventor: OBEREGGER WERNER [CA]; ZHOU FANG [US]; MAES PAUL [CA]; TURCHETTA STEFANO [IT]; JACKSON GRAHAM [IE]; MASSARDO PIETRO [IT]; SALEH MOHAMMAD ASHTY [CA]

Title: Pharmaceutical formulation containing a biguanide and an angiotensin antagonist

Applicant/Assignee: ANDRX LABS, LLC

Application No.: 11/628066   Filing Date: 27/May/2005

Abstract:

A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a angiotensin antagonist is herein disclosed and described.

Priority: US20040575259P Applic. Date: 2004-05-28; WO2005US18939 Applic. Date: 2005-05-27

Inventor: HAHN ELLIOT F [US]

Title: Crystalline and amorphous forms of beta-L-2'-deoxythymidine

Applicant/Assignee: NOVARTIS AG

Application No.: 11/807232   Filing Date: 25/May/2007

Abstract:

Physical forms of beta-L-2'-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2'-deoxythymidine can be used in the manufacture of other forms of beta-L-2'-deoxythymidine, or in pharmaceutical compositions. Particularly preferred uses are in the treatment of hepatitis B.

Priority: US2003-636349 Applic. Date: 2003-08-06; US20020401318P Applic. Date: 2002-08-06

Inventor: JONAITIS DAVID [US]; STORER RICHARD [GB]

Title: Thrombin-cleavable chimeric proteins

Applicant/Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Application No.: 10/492191   Filing Date: 11/Mar/2005

Abstract:

The invention relates to chimeric proteins comprising an artificial sequence for cleavage by thrombin, in which the activation peptide is fibrinopeptide A. Preferably, said chimeric proteins are derived from the zymogen of a serine protease such as PC or FX, by replacing the activation peptide of said zymogen with fibrinopeptide A, or a portion thereof, comprising at least amino acids P10 to P1 of said fibrinopeptide.

Priority: WO2002EP12191 Applic. Date: 2002-10-18; FR20010013492 Applic. Date: 2001-10-19

Inventor: LE BONNIEC BERNARD [FR]; MARQUE PIERRE-EMMANUEL [FR]; LOUVAIN VIRGINIE [FR]; CALMEL CLAIRE [FR]; BIANCHINI ELSA [FR]; AIACH MARTINE [FR]

Title: Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions

Applicant/Assignee: OSTEOLOGIX A/S

Application No.: 11/269289   Filing Date: 07/Nov/2005

Abstract:

Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.

Priority: DK20030001820 Applic. Date: 2003-12-09; DK20030000932 Applic. Date: 2003-06-20; DK20030000691 Applic. Date: 2003-05-07; WO2004DK00328 Applic. Date: 2004-05-06; WO2005DK00140 Applic. Date: 2005-02-28; WO2005DK00404 Applic. Date: 2005-06-17; WO2005DK00401 Applic. Date: 2005-06-17; US20030528442P Applic. Date: 2003-12-09

Inventor: HANSEN CHRISTIAN [DK]; NILSSON HENRIK [DK]; CHRISTGAU STEPHAN [DK]; ANDERSEN JENS E T [DK]

Title: Hyperglycosylated polypeptide variants and methods of use

Applicant/Assignee: ALIOS BIOPHARMA, INC

Application No.: 11/351163   Filing Date: 08/Feb/2006

Abstract:

The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites, as well as erythropoietin and darbepoetin alfa, each of which are linked to a penetrating peptide that facilitates translocation of a substance across a biological barrier as well as pharmaceutical compositions, including oral formulations, of the same.

The present invention further provides oral formulations of hyperglycosylated or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic.

The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.

Priority: US2006-330917 Applic. Date: 2006-01-11; US2005-200531 Applic. Date: 2005-08-08; US20040600202P Applic. Date: 2004-08-09; US20040600134P Applic. Date: 2004-08-09; US20040604280P Applic. Date: 2004-08-24; US20040604415P Applic. Date: 2004-08-24

Inventor: BLATT LAWRENCE M [US]; SEIWERT SCOTT D [US]; HONG JIN [US]

Title: Promotion of peroxisomal catalase function in cells

Applicant/Assignee: WAYNE STATE UNIVERSITY

Application No.: 10/533124   Filing Date: 27/Dec/2005

Abstract:

The molecular mechanisms of peroxisome biogenesis have begun to emerge: in contrast, relatively little is known about how the organelle functions as cells age. The present inventors characterized age-related changes in peroxisomes of human cells and showed that aging compromises peroxisomal targeting signal 1 (PTS 1) protein import, with the critical antioxidant enzyme, catalase, especially affected. The number and appearance of peroxisomes are altered in these cells, and the organelles accumulate the PTS1-import receptor, Pex5p, on their membranes. Concomitantly, cells produce increasing amounts of the toxic metabolite, H2O2, and this increased load of reactive oxygen species (ROS) may further reduce peroxisomal protein import and exacerbate the effects of aging.

Disclosed are novel compositions and methods for restoring catalase in peroxisomes by use of targeted catalase modified at its C-terminus and/or N-terminus, optionally in combination with polypeptides which promote cellular uptake of proteins, to prevent or overcome the changes that follows aging or that are associated with a number of diseases or disorders.

Priority: US20020422100P Applic. Date: 2002-10-30; WO2003US34512 Applic. Date: 2003-10-30

Inventor: TERLECKY STANLEY R [US]; WALTON PAUL A [CA]

Title: Purified Arabinogalactan-Protein (AGP) composition useful in the treatment psoriasis and other disorders

Applicant/Assignee: LUPIN LABORATORIES LIMITED LUPIN LIMITED

Application No.: 10/931814   Filing Date: 01/Sep/2004

Abstract:

A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of Argemone mexicana plant is described. Also described is a purified Arabinogalactan-Protein (AGP) composition isolated from the leaves and/or stems of Argemone mexicana plant, which has one or more of the following effects: immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFN-gamma inhibition, or IL-10 induction

keratinocyte proliferation inhibition, keratolytic activity and inhibitory activity in Mouse Ear Swelling test (MEST).

Priority:

Inventor: ARORA SUDERSHAN KUMAR [IN]; SRIVASTAVA VANDITA [IN]; WALUNJ SAMEER SHANKAR [IN]

Title: Solid preparation containing chitosan powder and process for producing the same

Applicant/Assignee: DAINIPPON SUMITOMO PHARMA CO., LTD

Application No.: 10/048063   Filing Date: 07/Aug/2000

Abstract:

A colonic delivery solid preparation containing chitosan powder, which can control the dissolution of a medicament therefrom in the large intestine and release the medicament contained therein specifically in the large intestine, obtained by successively coating a medicament-containing solid material with (1) a water-insoluble polymer having a chitosan powder dispersed therein and (2) an enteric polymer

and a solid preparation containing chitosan powder, which can partly release a medicament in the stomach and, after passing through the small intestine, disintegrate at an accelerated rate in the large intestine and release a medicament in the large intestine, obtained by coating a medicament-containing solid material with a water-insoluble polymer having a chitosan powder dispersed therein.

Priority: JP19990224777 Applic. Date: 1999-08-09; WO2000JP05279 Applic. Date: 2000-08-07

Inventor: SHIMONO NORIHITO [JP]; MORI MASAAKI [JP]; HIGASHI YUTAKA [JP]

Title: PROTECTIVE FACTORS AGAINST INFLAMMATION, BURNS AND NOXIOUS STIMULI

Applicant/Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREWUNIVERSITY OF JERUSALEM

Application No.: 11/750408   Filing Date: 18/May/2007

Abstract:

Peptide factors isolated from skin following exposure to chemical or thermal injury and treatment with iodine preparations are capable of reducing or ameliorating the extent of injury when administered to other animals. Specific peptides, including fragments of histone H2A and fibrinopeptide A, and preferred derivatives of these peptides are disclosed. Pharmaceutical compositions and methods of using these peptides are also disclosed. The extracts, peptides and pharmaceutical compositions according to the invention are useful for the prevention and treatment of inflammatory conditions and exposure to noxious stimuli.

Priority: IL20010145181 Applic. Date: 2001-08-29; US2004-790888 Applic. Date: 2004-03-01; WO2002IL00713 Applic. Date: 2002-08-29; US2006-527162 Applic. Date: 2006-09-25; WO2005IL00328 Applic. Date: 2005-03-23; US20040555334P Applic. Date: 2004-03-23; US20060831216P Applic. Date: 2006-07-17

Inventor: WORMSER URI [IL]

Title: Pharmaceutical compositions comprising cross-linked small molecule amine polymers

Applicant/Assignee: ILYPSA, INC

Application No.: 10/980991   Filing Date: 03/Nov/2004

Abstract:

Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.

Priority: US2004-965044 Applic. Date: 2004-10-13; US2004-806495 Applic. Date: 2004-03-22; US2003-701385 Applic. Date: 2003-11-03

Inventor: CONNOR ERIC [US]; CHARMOT DOMINIQUE [US]; CHANG HAN-TING [US]; ROGER FLORENCE [CH]; KLAERNER GERRIT [US]; NGUYEN SON HOAI [US]; MILLS JONATHAN [US]; BUYSSE JERRY M [US]; LEE ANGELA [US]; MADSEN DEIDRE [US]; SHAO JUN [US]; COPE MICHAEL J [US]; FORDTRAN JOHN [US]

Title: Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD

Application No.: 10/419536   Filing Date: 21/Apr/2003

Abstract:

A solid dosage form for oral administration to a patient comprising a core tablet sheathed in an annular body of compressed powder or granular material is provided. A preferred embodiment of the solid dosage form reduces contact of the active ingredient in solid form with the mucosa lining the gastrointestinal tract, which is particularly advantageous for delivering an ulcerative drug. A tool set comprising a columnar punch and a punch assembly comprising an annular punch and core rod, and a tableting process for making the solid dosage form are also provided.

Priority: US2002-291619 Applic. Date: 2002-11-12; US20010342442P Applic. Date: 2001-12-24; US20020361821P Applic. Date: 2002-03-04

Inventor: LERNER E ITZHAK [IL]; ROSENBERGER VERED [IL]; AQUA OFER [IL]; FLESHNER-BARAK MOSHE [IL]

Title: Utilization of Dialkylfumarates

Applicant/Assignee: BIOGEN IDEC INTERNATIONAL AG

Application No.: 11/765563   Filing Date: 20/Jun/2007

Abstract:

The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.

Priority: DE19981053487 Applic. Date: 1998-11-19; US2002-197077 Applic. Date: 2002-07-17; US2001-831620 Applic. Date: 2001-05-10; WO1999EP08215 Applic. Date: 1999-10-29

Inventor: JOSHI RAJENDRA KUMAR [CH]; STREBEL HANS-PETER [CH]

Title: Synergistic composition for treating leukemia

Applicant/Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH

Application No.: 10/613122   Filing Date: 07/Jul/2003

Abstract:

The present invention provides a method of treating acute and chronic myeloid leukemia (AML & CML) and lymphoid leukemia, said method comprising administering a pharmaceutical composition comprising pharmaceutically effective amount of chlorogenic acid (CA) and 3-o-p-Coumaryl quinic acid (PCQ) isolated from any plant parts of Piper betel or any other source, both individually or in a synergistic combination optionally along with pharmaceutically acceptable additives.

Priority: US20020393750P Applic. Date: 2002-07-08

Inventor: BANDYOPADHYAY SANTU [IN]; CHANDRA PAL BIKASH [IN]; BHATTACHARYA SAMIR [IN]; CHANDRA ROY KESHAB [IN]; BANDYOPADHYAY GAUTAM [IN]

Title: Hydrocephalus Treatment

Applicant/Assignee: SHINSHU TLO CO., LTD

Application No.: 10/579297   Filing Date: 19/Nov/2004

Abstract:

A method and compound for treatment of hydrocephalus is presented. Hepatocyte growth factor (HGF) is administered intraventricularly.

Priority: US20030524094P Applic. Date: 2003-11-20; WO2004IB04459 Applic. Date: 2004-11-19

Inventor: TADA TSUYOSHI [JP]; NAKAMURA TOSHIKAZU [JP]

Title: Compositions comprising large and small binding fragments of antibodies against the same toxin

Applicant/Assignee: THE SECTETARY OF STATE FOR DEFENCE

Application No.: 10/559148   Filing Date: 03/Jun/2004

Abstract:

A pharmaceutical composition comprising (i) a first specific binding agent selected from an antibody or a large binding fragment of an antibody which specifically binds a target toxin, and (ii) a second specific binding agent which comprises a small binding fragment of an antibody which binds said toxin. The compositions are used in the treatment of toxin poisoning, for example following exposure to toxins such as Botulinum toxins.

Priority: GB20030012642 Applic. Date: 2003-06-03; WO2004GB02351 Applic. Date: 2004-06-03

Inventor: HOLLEY JANE LOUISE [GB]; MAYERS CARL NICHOLAS [GB]; WHITFIELD DAVID [GB]; BROOKS TIMOTHY JOHN GILBY [GB]

Title: Utilization of dialkylfumarates

Applicant/Assignee: BIOGEN IDEC INTERNATIONAL GMBH

Application No.: 11/765578   Filing Date: 20/Jun/2007

Abstract:

The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.

Priority: DE19981053487 Applic. Date: 1998-11-19; US2002-197077 Applic. Date: 2002-07-17; US2001-831620 Applic. Date: 2001-05-10; WO1999EP08215 Applic. Date: 1999-10-29

Inventor: JOSHI RAJENDRA KUMAR [CH]; STREBEL HANS-PETER [CH]

Title: Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion

Applicant/Assignee: MAI DE LTD

Application No.: 11/033523   Filing Date: 12/Jan/2005

Abstract:

The present invention relates to novel amorphous form of [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl) (erlotinib hydrochloride), to solid amorphous dispersion of erlotinib hydrochloride and a carrier such as PVP or solid PEG, to processes for their preparations, to pharmaceutical compositions containing them and to method of treatment using the same. The amorphous form or solid amorphous dispersion of erlotinib hydrochloride obtained in this invention is useful in preparing pharmaceutical dosage forms.

Priority:

Inventor: HUANG LE [CN]

Title: Modification of clostridial toxins for use as transport proteins

Applicant/Assignee: INVENT DCU LIMITED

Application No.: 09/676053   Filing Date: 28/Sep/2000

Abstract:

A chemical conjugate for treating a nerve cell related disorder is provided. This conjugate includes an active or inactive Clostridial toxin having specificity for a target nerve cell. The toxin is conjugated to a drug or other bioactive molecule without affecting the toxin's ability to enter the target nerve cell.

Priority: GB19940010871 Applic. Date: 1994-05-31; US1997-750101 Applic. Date: 1997-05-01

Inventor: DOLLY JAMES OLIVER [IE]; WHEELER LARRY ALLEN [US]; AOKI KEI ROGER [US]; GARST MICHAEL ELWOOD [US]

Title: Modified l-nucleic acid

Applicant/Assignee: NOXXON PHARMA AG

Application No.: 10/493569   Filing Date: 25/Jul/2005

Abstract:

The present invention relates to a modified L-nucleic acid, comprising a L-nucleic acid part and a non-L-nucleic acid part, whereby the L-nucleic acid part is conjugated to the non-L-nucleic acid part and the conjugation of the L-nucleic acid part with the non-L-nucleic acid past leads to a slowed elimination out of the organism, in comparison with a L-nucleic acid which only comprises the L-nucleic acid part, said L-nucleic acid part being a spiegelmer.

Priority: EP20010125630 Applic. Date: 2001-10-26; EP20020017300 Applic. Date: 2002-08-01; WO2002EP11950 Applic. Date: 2002-10-25

Inventor: LANGE CHRISTIAN [DE]; ESCHGFAELLER BERND [CH]; KLUSSMANN SVEN [DE]

Title: Compositions for treatment of inflammatory diseases

Applicant/Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA

Application No.: 11/347148   Filing Date: 02/Feb/2006

Abstract:

Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.

Priority: US2004-023812 Applic. Date: 2004-12-28; US20040537766P Applic. Date: 2004-01-20